Keyphrases
Graft-versus-host Disease (GvHD)
100%
Bortezomib
100%
Unrelated Donor Transplantation
100%
HLA-mismatched Unrelated Donor
100%
Graft-versus-host Disease Prophylaxis
100%
Reduced-intensity Conditioning
66%
Hematopoietic Stem Cell Transplantation
50%
HLA Matching
50%
Cumulative Incidence
50%
Short Course
33%
Mismatched Related Donor
33%
Non-relapse Mortality
33%
Hematological Malignancies
16%
Prospective Randomized Trial
16%
Improved Outcomes
16%
Phase II Trial
16%
Randomized Evaluation
16%
Immune Reconstitution
16%
Tacrolimus
16%
Natural Killer Cells
16%
Transplantation
16%
Immune Recovery
16%
Reconstitution
16%
Cell Infusion
16%
Methotrexate
16%
Peripheral Blood Stem Cells
16%
Protease Inhibitors
16%
Overall Survival
16%
Antithymocyte Globulin
16%
Progression-free Survival
16%
HLA-A
16%
Unrelated Hematopoietic Stem Cell Transplantation
16%
Immunomodulatory Properties
16%
DRB1
16%
Host Survival
16%
T-cell Replete
16%
HLA-DQB1
16%
T Cell Depletion
16%
CD8+ T
16%
Immunology and Microbiology
Graft-Versus-Host Disease
100%
Conditioning
80%
Hematopoietic Stem Cell Transplantation
80%
Immune Reconstitution
40%
Chronic Graft Versus Host Disease
40%
Natural Killer Cell
20%
Cytotoxic T-Cell
20%
Tacrolimus
20%
Acute Graft Versus Host Disease
20%
Anti-Thymocyte Globulin
20%
T Cell Depletion
20%
Peripheral Blood Stem Cell
20%
Methotrexate
20%
Overall Survival
20%
Progression Free Survival
20%
T Cell
20%
Proteasome
20%